X.Y. Hua Macau University of Science and Technology Macau China
Dr. Xu is the Associate Professor at Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology. He specializes in researches on pharmacology, cardiovascular and metabolic diseases, and discovery and evaluation of effective components from Chinese Medicines. His research interests mainly include: (1) study of Chinese Medicines on diabetes; (2) effects and mechanism of natural products on cardio-cerebrovascular disease; (3) development and application of alive cell immobilized chromatography on the R&D of Chinese Medicines. He has been awarded prizes including the Second Prize of Science and Technology Invention Award Category of the 2016 Macau Science and Technology Award (the second awardee), and Third Prize of 2011 Science and Technology Award of Jiangsu Province (the seventh awardee), etc. for academic performance.
L. Scotti Federal University of Paraíba João Pessoa, PB Brazil
Luciana Scotti received her Ph.D. in Cosmetology and Molecular Modeling at the University of São Paulo, Brazil. She made 3 years of Post-Doctorate in Pharmaceuticals at the Laboratory of Planning and Synthesis of Potentially Active Chemotherapies in Tropical Endemics, Faculty of Pharmaceutical Sciences, USP. She has experience in Pharmacology Biochemistry and Molecular acting mainly in the following areas: natural products, Molecular Modeling, QSAR, and Chemometrics. She is the professor of the Post-Graduate Program of Bioactive Natural and Synthetic Products of the Federal University of Paraíba, Brazil.
M. Shammas Harvard (Dana Farber) Cancer Institute Boston, MA USA
Dr. Shammas is employed as a Lead Scientist in the field of Translational Cancer Research at Harvard (Dana Farber) Cancer Institute, Boston, USA. His research focuses on understanding mechanisms underlying genomic instability and their translational significance in cancer, including Barrett’s esophageal adenocarcinoma. He has developed novel tools/assay systems to study genomic evolution in cancer and has identified key targets and novel drugs to inhibit/reduce genomic evolution, whether intrinsic to cancer cell or that induced/increased by chemotherapeutic agents. These drugs have potential to inhibit tumor growth, overcome/minimize harmful genomic impact of chemotherapy and inhibit/delay progression of cancer to advanced and more aggressive stages. He is a co-author over 60 scientific publications including book chapters and has trained a number of students (undergraduate, graduate), postdoctoral fellows and clinical fellows. He has served and/or serving as Principal Investigator, Co-Principal Investigator and/or Co-investigator on several research grants from the NIH (USA), including R01 grant or even larger grants, including Program Project and Specialized Programs of Research Excellence grants from NIH. He is serving or has served as a Founding Editor, Editor, Lead Guest Editor and/or Guest Associate Editor for several scientific journals, a Grant Reviewer, and as an External Examiner for PhD students for Universities abroad.
H. Zaid Al-Qasemi Educational Research Center Baka Israel
Dr. Hilal Zaid is presently serving as a Head of Al-Qasemi Educational Research Center, Al-Qasemi Academic College, Baka, Israel. He completed his M.Sc. from the department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israelin 1996. He further obtained PhD from the same university in 2005. He is also a Management Committee member of European Cooperation in Science and Technology (COST) Action N°CA15129, titled "Diagnosis, Monitoring and Prevention of Exposure-Related Noncommunicable Diseases (DiMoPEx)".
Francis J. Castellino (14643 citations) Kleiderer-Pezold Professor of Biochemistry Director, W.M. Keck Center for Transgene Research Dean Emeritus, College of Science 230 Raclin-Carmichael Hall, University of Notre Dame Notre Dame, IN 46556 USA